| ￥1980 在线订购包邮(港澳台除外) | |
| A02264-40 | |
|
|
|
|
|
|
|
|
|
| 咨询产品问题 | |
| Specificity | This product is specific for Ixekizumab. |
| Host Species | Rabbit |
| Immunogen | Ixekizumab |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||||||
|
|||||||||
| Form | Lyophilized |
| Storage Buffer | Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide. |
| Reconstitution | Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. |
| Storage Instructions | The lyophilized product remains stable for 1 year at -20℃ from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8℃ or for 12 months at -20℃ or below. Avoid repeated freezing and thawing cycles. |
| Purification | Protein A affinity column |
| Isotype | Rabbit IgG, κ |
| Clonality | Monoclonal |
| Clone ID | 19F6 |
| Note | GenScript can customize this product per customer's request including product size, buffer components, etc. |
»
BLI (Biolayer interferometry) binding affinity measurements of MonoRab™ Anti-Ixekizumab Antibody (19F6), mAb, Rabbit (GenScript, A02264) to Ixekizumab.
Ixekizumab captured on HFC (Anti-Human IgG Fc) Probes can bind MonoRab™ Anti-Ixekizumab Antibody (19F6), mAb, Rabbit with a dissociation constant (KD) of 8.84E-10M. »
Anti-Ixekizumab Antibody (19F6)) or (29B12) inhibits the binding of Ixekizumab to IL-17A.
Coating antigen: Ixekizumab 30 µg/ml.
IL-17A (GenScript, Z03228) final concentration: 20 ng/ml.
Anti-Ixekizumab antibody dilutions start from 30 μg/ml.
MonoRab™ Anti-Ixekizumab Antibody (19F6), mAb, Rabbit (GenScript, A02264) demonstrated inhibitory properties with an IC50 value of 0.32 µg/ml and MonoRab™ Anti-Ixekizumab Antibody (29B12), mAb, Rabbit (GenScript, A02265) demonstrated inhibitory properties with an IC50 value of 1.11 µg/ml »
Standard curve of Ixekizumab sandwich ELISA by A02264 (19F6) and A02265 (29B12).
In this ELISA assay, MonoRab™ Anti-Ixekizumab Antibody (19F6), mAb, Rabbit (GenScript, A02264) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Ixekizumab Antibody (29B12), mAb, Rabbit (GenScript, A02265) conjugated with Biotin was used as a detection antibody at a concentration of 0.5 μg/ml.
In this ELISA assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square equal to 0.99921. The typicaldynamic range of the assay is 1-64 ng/mL and its sensitivity of detecting Ixekizumab is up to 1 ng/ml. »
MRD analysis of the detection of Ixekizumab in biological matrix.
The MRD is the minimum dilution necessary for the detection of Ixekizumab in biological matrix with least interference. Serum samples from cynomolgus monkey were serially diluted to determine the MRD of this assay, and the test result suggestedthat MRD was as 1:10.
In this ELISA assay, MonoRab™ Anti-Ixekizumab Antibody (19F6), mAb, Rabbit (GenScript, A02264) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Ixekizumab Antibody (29B12), mAb, Rabbit (GenScript, A02265) conjugated with Biotin was used as a detection antibody at a concentration of 0.5 μg/ml. »
Specificity analysis of the detection of Ixekizumab.
Ixekizumab standard samples at 8 concentrations were spiked with 100 ng/mL of human IgG4. The test result demonstrated that the concentration of human IgG4 did not interfere with the detection of Ixekizumab.
In this ELISA assay, MonoRab™ Anti-Ixekizumab Antibody (19F6), mAb, Rabbit (GenScript, A02264) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Ixekizumab Antibody (29B12), mAb, Rabbit (GenScript, A02265) conjugated with Biotin was used as a detection antibody at a concentration of 0.5 μg/ml. »
| Target Background | Ixekizumab, marketed under the brand name Taltz, is an injectable medication employed for the management of autoimmune diseases. It is classified as a humanized monoclonal antibody and operates by binding to interleukin 17A, effectively neutralizing its activity and consequently reducing inflammation. |
| Synonyms | Ixekizumab, Taltz, IL-17A Antagonist, Anti-IL-17A Antibody, LY2439821, LY-2439821 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
